Standout Papers

Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With... 2023 2026 202474
  1. Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes (2023)
    Aditi R. Saxena, Juan P. Frías et al. JAMA Network Open

Immediate Impact

10 from Science/Nature 73 standout
Sub-graph 1 of 20

Citing Papers

GLP-1-based therapies for diabetes, obesity and beyond
2025 Standout
Adipose tissue retains an epigenetic memory of obesity after weight loss
2024 StandoutNature
6 intermediate papers

Works of Donal Gorman being referenced

Tolerability, safety and pharmacodynamics of oral, small‐molecule glucagon‐like peptide‐1 receptor agonist danuglipron for type 2 diabetes: A 12‐week, randomized, placebo‐controlled, Phase 2 study comparing different dose‐escalation schemes
2023
Efficacy and Safety of Oral Small Molecule Glucagon-Like Peptide 1 Receptor Agonist Danuglipron for Glycemic Control Among Patients With Type 2 Diabetes
2023 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Donal Gorman 227 222 108 201 24 879
H. Rochlitz 168 180 64 325 17 813
Elena Giordano 188 215 177 180 26 1.1k
Isabelle Dumont 109 235 91 209 52 958
Christine Brennan 125 203 44 121 22 852
Carol A. Maggio 409 172 152 480 14 1.1k
Michael T. Pedrini 299 300 46 299 22 1.0k
Rosaria De Iasio 371 142 94 206 22 938
Luciana C. Caperuto 138 313 31 274 35 1.1k
Chak Leung Au 295 306 94 190 34 1.1k
Wasaku Koyama 245 255 42 429 26 1.1k

All Works

Loading papers...

Rankless by CCL
2026